Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-05-30
2006-05-30
Low, Christopher S. F. (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C548S321500, C548S492000, C548S517000, C548S527000, C544S360000, C546S278400, C530S331000
Reexamination Certificate
active
07053056
ABSTRACT:
This invention is directed to novel oxamyl dipeptide ICE/ced-3 family inhibitor compounds. The invention is also directed to pharmaceutical compositions containing these compounds, as well as to the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury, and for the preservation of organs that are to undergo a transplantation procedure.
REFERENCES:
patent: 5869519 (1999-02-01), Karanewsky et al.
patent: 5877197 (1999-03-01), Karanewsky et al.
patent: 5968927 (1999-10-01), Karanewsky et al.
patent: 6197750 (2001-03-01), Karanewsky et al.
patent: 6235899 (2001-05-01), Bouchet et al.
patent: 618 223 (1994-10-01), None
patent: 623 592 (1994-11-01), None
patent: WO 97/22619 (1997-06-01), None
patent: WO 98/10778 (1998-03-01), None
patent: WO 99/03852 (1999-01-01), None
patent: WO 00/01666 (2000-01-01), None
patent: WO 00/23421 (2000-04-01), None
patent: WO 01/00658 (2001-01-01), None
patent: WO 01/51462 (2001-07-01), None
patent: WO 01/81330 (2001-11-01), None
Chapman K., “Synthesis of a Potent, Reversible Inhibitor of Interleukin-1β Converting Enzyme,”Bioorganic&Medicinal Chemistry Letters 2(6):613-618,1992.
Cheung et al., “Synthesis of 3-Amino-3-Vinylpropanoic Acid and its Conversion to 4-Amino-5-Hydroxy-4,5-Dihydrofuran-2-one Hydrochloride (HAD), A Cyclic Stabilised Form of Aspartate 1-Semialdehyde Hydrocholride,”Tetrahedron 53(46):15807-15812, 1997.
de Lange et al., “Asymmetric 1, 4-Additions to 5-Alkoxy-2(5H)-Furanones Enantioselective Synthesis and Absolute Configuration Determination of γ-Amino-α-Butyrolactones and Amino Diols,”Tetrahedron 45(21):6799-6818, 1989.
Faber et al., “Catalytic Kinetic Resolution of 5-Alkoxy-2(5H)-Furanones,”Tetrahedron 50(16):4775-4794,1994.
Feringa et al., “Asymmetric Synthesis of 2-Amino-1, 4-Diols,”Tetrahedron Letters 29(11):1303-1306, 1988.
Feringa et al., “1, 4-Additions of Amines to 5-Methoxyfuran-2(5H)-One; An Efficient Synthesis of Amino Diols,”Heterocycles 27(5):1197-1205, 1988.
Furuichi et al., “Common Synthetic Strategy for Optically Active Cyclic Terpenoids having a 1,1,5-Trimethyl-Trans-Decalin Nucleus: Syntheses of (+)-Acuminolide, (−)-Spongianolide A, and (+)-Scalarenedial,”Tetrahedron 57, pp. 8425-8442, 2001.
Gonzalez et al., “Pseudoesters and Derivatives. Part38.11,3-Dipolar Cycloadditions of Aryl Azides and an Aziridine, Via Azomethine Ylide, to 2(5H)-Furanones Substituted at the 5-Position by Methoxy and Sulfur Bearing Groups,”Heterocycles 52(1):237-251, 2000.
Leblanc et al., “Star in the Alkoxy Lactone Series: The Discovery of DFP, A Potent and Orally Active Cox-2 Inhibitor,”Bioorganic&Medicinal Chemistry Letters 9, pp. 2207-2212, 1999.
Lubben et al., “Asymmetric Synthesis of β-Lactams via Amine Additions to 5(R)-Menthyloxy-2[5H]-Furanone,”Tetrahedron: Asymmetry 2(8):755-778, 1991.
Ilugunin et al., “Protease activity of m-vitro transcribed and translated caenorhabditis elegans cell death gene (ced-3) product” J. Biol. Chem., Feb. 16, 1996, 271(7) 3517-12 abstract only, 1996.
Juan TS et al., “Molecular characterization of mouse and rat CPP32 beta gene encoding a cycteine protease resembling interleukin-1 beta convesting enzyme and CED-3” Oncogene, 13(4)749-55, Aug. 15, 1996 (Absrtact only).
Gagliardini et al. Prevention of Vertebrate Neuronal Death by the crmA Gene, Science vol. 263, Feb. 11, 1994 pp. 826-828.
Marx. Cell Death Studies Yield Cancer Clues; Science vol. 259, Feb. 5, 1993, pp. 760-761.
Sleath et al., Substrate Specificity of the Protease that Processes Human Interleukin—1.beta., The Journal of Biological Chemistry, vol. 265, No. 24, pp. 14526-14528, Aug. 25, 1990.
Dinh Thang
Karanewsky Donald S.
Linton Steven D.
Ternansky Robert J.
Idun Pharmaceuticals, Inc.
Low Christopher S. F.
Lukton David
LandOfFree
C-terminal modified oxamyl dipeptides as inhibitors of the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with C-terminal modified oxamyl dipeptides as inhibitors of the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and C-terminal modified oxamyl dipeptides as inhibitors of the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3637973